Rapport Therapeutics, Inc.
RAPP
$10.06
-$0.41-3.92%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 7.54M | 6.32M | 6.10M | 5.11M | 4.59M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 27.11M | 23.52M | 21.64M | 20.80M | 17.09M |
| Operating Income | -27.11M | -23.52M | -21.64M | -20.80M | -17.09M |
| Income Before Tax | -24.06M | -19.98M | -17.54M | -18.12M | -22.67M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -24.06M | -19.98M | -17.54M | -18.12M | -22.67M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -24.06M | -19.98M | -17.54M | -18.12M | -22.67M |
| EBIT | -27.11M | -23.52M | -21.64M | -20.80M | -17.09M |
| EBITDA | -26.86M | -23.26M | -21.42M | -20.59M | -16.94M |
| EPS Basic | -0.68 | -0.57 | -0.50 | -1.70 | -11.07 |
| Normalized Basic EPS | -0.43 | -0.36 | -0.31 | -1.06 | -4.67 |
| EPS Diluted | -0.68 | -0.57 | -0.50 | -1.70 | -11.07 |
| Normalized Diluted EPS | -0.43 | -0.36 | -0.31 | -1.06 | -4.67 |
| Average Basic Shares Outstanding | 35.27M | 35.07M | 34.86M | 10.67M | 2.05M |
| Average Diluted Shares Outstanding | 35.27M | 35.07M | 34.86M | 10.67M | 2.05M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |